{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics","Multiomics"],"center_name":["Laboratory for Cell and Molecular Biology, The Integrated Cancer Prevention Center, Tel Aviv Medical Center"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA114851"],"scientific_name":["Homo sapiens"],"tag":["xref:PubMed:18413748"],"long_description":["CD24 is a potential oncogene reported to be overexpressed in a large variety of human malignancies. We have shown that CD24 is overexpressed in 90% of colorectal tumors at a fairly early stage in the multistep process of carcinogenesis. Anti-CD24 monoclonal antibodies (mAb) induce a significant growth inhibition in colorectal and pancreatic cancer cell lines that express the protein. This study is designed to investigate further the effects of CD24 down-regulation using mAb or small interfering RNA in vitro and in vivo. Western blot analysis showed that anti-CD24 mAb induced CD24 protein down-regulation through lysosomal degradation. mAb augmented growth inhibition in combination with five classic chemotherapies. Xenograft models in vivo showed that tumor growth was significantly reduced in mAb-treated mice. Similarly, stable growth inhibition of cancer cell lines was achieved by down-regulation of CD24 expression using short hairpin RNA (shRNA). The produced clones proliferated more slowly, reached lower saturation densities, and showed impaired motility. Most importantly, down-regulation of CD24 retarded tumorigenicity of human cancer cell lines in nude mice. Microarray analysis revealed a similar pattern of gene expression alterations when cells were subjected to anti-CD24 mAb or shRNA. Genes in the Ras pathway, mitogenactivated protein kinase, or BCL-2 family and others of oncogenic association were frequently down-regulated. As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 is a potential target for early intervention in the prevention and treatment of cancer. Overall design: The study compared gene expression profiles between human CRC cells HT29 before and after expression of 1 and 2 shRNA vectors directed at the human CD24 gene, GFP control gene, HT29 cells and Colo357, human pancreatic cancer cells, before and after the inhibition of the CD24 molecule using 72h treatment with anti-CD24 monoclonal antibodies."],"repository":["ENA"],"description_synonyms":["Therapy, Interfering RNA, Carcinoma, RNA, Trans-Acting, Trans-Acting siRNA, R13-Ag, Neoplasms, Monoclonal Antibody, malignant neoplasm of body of pancreas, pancreatic neoplasm, Small Hairpin, familial, Pancreas Cancer, nectadrin, M1/69-J11D heat stable antigen, shRNA, pancreas, HSA, Monoclonal, Cd24, Pancreas Cancers, Pancreas Neoplasm, Pancreatic Neoplasm, Short, Repeat-Associated siRNA., Small Hairpin RNA, Short Interfering, Repeat Associated siRNA, Small, Antibody, Short Hairpin RNA, Ca tail of pancreas, Ca head of pancreas, small cell lung carcinoma cluster 4 antigen, Trans Acting, Monoclonal Antibodies, Pancreatic Cancer, Scan RNA, Small Scan, Small Scan RNA, Neoplasm, Pancreatic Acinar, pancreatic carcinoma, Pancreatic, Short Interfering RNA, Cancer of the Pancreas, Hairpin RNA, Scan, Pancreatic Carcinomas, Carcinomas, treatment, malignant neoplasm of tail of pancreas, pancreatic tumor, scnRNA, Small Interfering RNA, lymphocyte antigen 52, Cancer of Pancreas, Pancreatic Carcinoma, malignant neoplasm of head of pancreas, Acinar Carcinoma, Cancers, Pancreatic Cancers, Repeat Associated, Ly-52, Treatments, Pancreas, INSDC_feature:ncRNA, Pancreatic Acinar Carcinoma, Short Hairpin, X62 heat stable antigen, Repeat-Associated, Therapeutic, Ca body of pancreas, siRNA, Trans Acting siRNA, disease management, Therapies, CD24A, Treatment, ly-52, PNCA, Pancreas Neoplasms, Pancreatic Acinar Carcinomas, CD24, tasiRNA, Acinar Carcinomas, Small cell lung carcinoma cluster 4 antigen, pancreatic tumour, pancreas neoplasm, Cancer"],"name_synonyms":["Human, Modern., human being, Man (Taxonomy), Homo sapiens, man, Man, human, Modern Man"],"additional_accession":[]},"is_claimable":false,"name":"Homo sapiens","description":"Targetting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or siRNA","dates":{"last_updated":"2025-09-24","first_public":"2014-02-11"},"accession":"PRJNA114851","cross_references":{"GEO":["GSE15102"],"taxon":["9606"],"PubMed":["18413748"]}}